IQAI Stock Overview
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
IQ-AI Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.029 |
| 52 Week High | UK£0.061 |
| 52 Week Low | UK£0.015 |
| Beta | 2.9 |
| 1 Month Change | 60.27% |
| 3 Month Change | 36.05% |
| 1 Year Change | -50.21% |
| 3 Year Change | -28.66% |
| 5 Year Change | -31.18% |
| Change since IPO | -19.31% |
Recent News & Updates
Shareholder Returns
| IQAI | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | -2.5% | -0.7% | 0.005% |
| 1Y | -50.2% | -7.6% | -4.5% |
Return vs Industry: IQAI underperformed the UK Healthcare Services industry which returned -10.7% over the past year.
Return vs Market: IQAI underperformed the UK Market which returned -4.8% over the past year.
Price Volatility
| IQAI volatility | |
|---|---|
| IQAI Average Weekly Movement | 11.3% |
| Healthcare Services Industry Average Movement | 3.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: IQAI is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: IQAI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Trevor Brown | https://www.imagingbiometrics.com/iq-ai-ltd |
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and IB StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.
IQ-AI Limited Fundamentals Summary
| IQAI fundamental statistics | |
|---|---|
| Market Cap | UK£5.34m |
| Earnings (TTM) | -UK£624.51k |
| Revenue (TTM) | UK£538.19k |
9.9x
P/S Ratio-8.6x
P/E RatioIs IQAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IQAI income statement (TTM) | |
|---|---|
| Revenue | UK£538.19k |
| Cost of Revenue | UK£10.52k |
| Gross Profit | UK£527.67k |
| Other Expenses | UK£1.15m |
| Earnings | -UK£624.51k |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0034 |
| Gross Margin | 98.05% |
| Net Profit Margin | -116.04% |
| Debt/Equity Ratio | 0% |
How did IQAI perform over the long term?
See historical performance and comparison